Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 5/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196742 | 0.82 | AKR1C3 (0.50) | AKR1C3AKR1C1F10F2ALDH1A1 | |
| SCHEMBL25269754 | 0.81 | AKR1C3 (0.80) | AKR1C3AKR1C1ALDH1A1NPSR1MAPT | |
| SCHEMBL6370497 | 0.80 | AKR1C3 (0.48) | AKR1C3AKR1C1F10F2ALDH1A1 | |
| SCHEMBL28983197 | 0.80 | AKR1C3 (0.70) | AKR1C3AKR1C1ALDH1A1NPSR1MAPT | |
| SCHEMBL24025380 | 0.77 | CHRM1 (0.56) | AKR1C3AKR1C1ALDH1A1NPSR1MAPT | |
| SCHEMBL24025633 | 0.77 | CHRM1 (0.56) | AKR1C3AKR1C1ALDH1A1NPSR1MAPT | |
| SCHEMBL7303194 | 0.76 | AKR1C3 (1.00) | AKR1C3AKR1C1ALDH1A1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL5737608 | 0.76 | F10 (0.67) | F10NPSR1MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL5735795 | 0.75 | F10 (0.66) | F10NPSR1MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL5735799 | 0.75 | F10 (0.66) | F10NPSR1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | AKR1C3 3831/4885AKR1C1 3642/4885F10 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.